
Sanofi and Regeneron Pharmaceuticals have announced that their Phase III ODYSSEY ESCAPE clinical trial evaluating Praluent (alirocumab) met its primary …
Aiforia deal to expand access to pathology AI
SMC accepts atogepant for acute migraine treatment in Scotland
New CCO Ogburn joins Cori Clinical

